Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Breast Cancer|Metastases|Bone Metastases in Subjects With Advanced Breast Cancer
BIOLOGICAL: Denosumab|DRUG: IV Bisphosphonates
Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr), Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100., Baseline and Week 13
Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx), Percent change from Baseline to Week 25 in Urinary N-telopeptide (uNTx) calculated using ((Week 25 value - Baseline value) / Baseline value) x 100., Baseline and Week 25|Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13, The number of participants achieving a 65% reduction or more in uNTx from Baseline at Week 13. Calculation used is ((Week 13 value - Baseline value) / Baseline value ) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%., Baseline and Week 13|Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25, The number of participants achieving a 65% reduction or more in uNTX from Baseline at Week 25. Calculation used is ((Week 25 value - Baseline value) / Baseline value) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%., Baseline and Week 25|Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline, Kaplan-Meier estimate of the median time from enrollment to the first occurrence of a reduction of uNTx of ≥ 65% compared to Baseline. For participants whose uNTx did not fall below 65% of the Baseline value, the time was censored at time of last evaluation of uNTx., Baseline to Week 57|Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX), Percent change from Baseline to Week 13 in type I serum C-telopeptide (CTX) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100., Baseline and week 13|Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX), Percent change from Baseline to Week 25 in type I serum C-telopeptide calculated using ((Week 25 value - Baseline value) / Baseline value) x 100., Baseline and Week 25|Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP), Percent change from Baseline to Week 13 in procollagen 1 N-terminal peptide calculated using ((Week 13 value - Baseline value) / Baseline value) x 100., Baseline and Week 13|Percent Change From Baseline to Week 25 in P1NP, Percent change from Baseline to Week 25 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Week 25 value - Baseline value) / Baseline value ) x 100., Baseline and Week 25|Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b), Percent change from Baseline to Week 13 in tartrate-resistant acid phosphatase 5b calculated using ((Week 13 value - Baseline value) / Baseline value) x 100., Baseline and Week 13|Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b), Percent change from Baseline to Week 25 in TRAP5b calculated using ((Week 25 value - Baseline value) / Baseline value) x 100., Baseline and Week 25|Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP), Percent change from Baseline to Week 13 in bone specific alkaline phosphatase (BSAP) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100., Baseline and Week 13|Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP), Percent change from Baseline to Week 25 in BSAP calculated using ((Week 25 value - Baseline value) / Baseline value) x 100., Baseline and Week 25|Percent Change From Baseline to Week 13 in Osteocalcin, Percent change from Baseline to Week 13 in osteocalcin calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100., Baseline and Week 13|Percent Change From Baseline to Week 25 in Osteocalcin, Percent change from Baseline to Week 25 in osteocalcin calculated using ((Week 25 value - Baseline value) / Baseline value) x 100., Baseline and Week 25|Time to First Skeletal Related Event, Skeletal Related Event (SRE) defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes)., Day 1 to Week 25|Number of Participants With Skeletal Related Events, Skeletal Related Events (SRE) are defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes)., From Day 1 to Week 25|Number of Participants With Hypercalcemia, Occurrence of grade 3 or 4 hypercalcemia according to the Common Terminology Criteria for Adverse Events (CTCAE) v3. A summary of hypercalcemia events is reported under adverse events., Day 1 to Week 57
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.